Anebulo up on promising data for cannabinoid intoxication therapy

Anebulo Pharmaceuticals

05/07/2022 13:41

** Shares of drug developer Anebulo Pharmaceuticals  ANEB.O 
rise ~13% to $6.20 premarket
    ** Co reports positive data from part A of an ongoing
mid-stage trial testing ANEB-001 to treat Acute Cannabinoid
Intoxication (ACI) (https://refini.tv/3NIXgmy)
    ** Data shows a highly statistically significant reduction
in key symptoms of ACI in patients receiving treatment - ANEB
    ** Study was conducted in Netherlands and enrolled 60
healthy adult occasional cannabis users; co plans to initiate
part B of study by end of Q3
    ** Expects to submit application by end of 2022 to start
U.S. trials of ANEB-001
    ** Stock down ~14.8% YTD as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))